Current Report Filing (8-k)
September 27 2021 - 8:47AM
Edgar (US Regulatory)
0001739426
false
00-0000000
0001739426
2021-09-27
2021-09-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
!
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 27, 2021
Osmotica
Pharmaceuticals plc
(Exact name of registrant as specified in its charter)
Ireland
(State or other jurisdiction
of incorporation)
|
|
001-38709
(Commission File Number)
|
|
Not Applicable
(IRS Employer
Identification No.)
|
400 Crossing Boulevard
Bridgewater, NJ
(Address of principal executive offices)
|
|
08807
(Zip Code)
|
(Registrant’s telephone number,
including area code): (908) 809-1300
Not Applicable
(Former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which
registered
|
Ordinary
Shares
|
OSMT
|
Nasdaq
Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
Item 7.01
|
Regulation FD Disclosure.
|
Beginning on September 27, 2021, Osmotica Pharmaceuticals plc
intends to use the presentation furnished herewith, or portions thereof, in one or more meetings or presentations with investors. A copy
of the presentation is furnished as Exhibit 99.1.
The information contained in this Current Report on Form 8-K,
including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in
such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
OSMOTICA PHARMACEUTICALS PLC
|
|
|
|
|
|
|
By:
|
/s/ Brian Markison
|
|
|
|
Brian Markison
|
|
|
Chief Executive Officer
|
|
|
|
Date: September 27, 2021
|
|
|
Osmotica Pharmaceuticals (NASDAQ:OSMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osmotica Pharmaceuticals (NASDAQ:OSMT)
Historical Stock Chart
From Jul 2023 to Jul 2024